Global Head Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Are concerned about the global economy. Do you feel like he is not as concerned as everybody elses. Steve is playing in the private markets. Those investments take a lot longer to mature. Whether he feels relaxed or not it is not easy to move illiquid assets if you are a black so if you are a Blackstone Group and one of the things we talked about was russia. Impossible not to talk about russia. Steve sits on an International Advisory panel. That is a position he still holds. I want you to hear Steve Schwarzman talking about the rifts in russia and how he plans to respond. I think in the short ...

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the pe...

Posted December 15th, 2020 for Novartis In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit...

In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the da...